Merck to cut jobs

Merck plans to eliminate 7,200 jobs by the end of 2011, according to their 2008 third quarter linkurl:financial report,;http://www.merck.com/newsroom/press_releases/financial/2008_1022.html released today. The cuts are part of ongoing restructuring efforts and come after a 28% profit plunge in the third quarter. The restructuring efforts began in 2005, and at the time the linkurl:pharmaceutical company;http://www.the-scientist.com/article/display/23391/ eliminated more than 10,000 jobs. The c

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Merck plans to eliminate 7,200 jobs by the end of 2011, according to their 2008 third quarter linkurl:financial report,;http://www.merck.com/newsroom/press_releases/financial/2008_1022.html released today. The cuts are part of ongoing restructuring efforts and come after a 28% profit plunge in the third quarter. The restructuring efforts began in 2005, and at the time the linkurl:pharmaceutical company;http://www.the-scientist.com/article/display/23391/ eliminated more than 10,000 jobs. The current cuts represent 10% of Merck's remaining job force; 40 % are US jobs, and a quarter of the cuts are of high-level or mid-level executive positions, although cuts will be made in every sector of the company. The company has suffered sluggish sales, especially of their vaccines, with third quarter revenue down 2%. Sales of prescription drugs between January and August of this year did not increase for the first time in 10 years, according to a linkurl:study;http://www.philly.com/philly/business/29553459.html by IMS Health. "With the right long-term strategy and our efforts to reshape Merck's business, including today's actions, I am confident we are building a solid foundation for achieving industry-leading performance in the future," Merck CEO Richard Clark said in the report.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo
Sapio Sciences logo

Sapio Sciences Introduces Biorepository Management Solution